文献速递肾小球疾病急性肾损伤

贝利尤单抗预防新发肾脏狼疮 flare 的效果

Effect of Belimumab on Preventing de novo Renal Lupus Flares.
PubMed 文献 · Kidney Int Rep · 2023-07-06

该研究基于 5 项 3 期临床试验,评估贝利尤单抗在无肾炎的系统性红斑狼疮(SLE)患者中预防新发肾脏 flare 的效果。1844 例患者中 136 例(7.4%)在 52 周随访期间出现新发肾脏 flare。低剂量静脉贝利尤单抗(1 mg/kg 每月)和皮下贝利尤单抗(200 mg 每周)与新发肾脏 flare 风险降低相关,而获批静脉剂量(10 mg/kg 每月)未见明确保护作用。

要点

  • 亚洲来源、基线抗 dsDNA 阳性及随访中泼尼松剂量增加与新发肾脏 flare 风险升高相关。
  • 皮下贝利尤单抗(200 mg 每周)与较低的新发肾脏 flare 风险相关。

核心结论

  • 在无肾炎的 SLE 患者中,加用低剂量静脉贝利尤单抗(1 mg/kg 每月)和皮下贝利尤单抗(200 mg 每周)似乎可预防肾脏 flare。
  • 获批静脉剂量(10 mg/kg 每月)未产生明确保护作用。
  • 研究证实亚洲 SLE 人群对肾脏受累具有显著易感性。

研究设计与样本

  • 研究利用 5 项 3 期临床试验数据,纳入无肾炎的 SLE 患者,接受加用贝利尤单抗或安慰剂治疗,采用 Cox 回归分析。
  • 共纳入 1844 例符合条件的患者,随访 52 周。

主要发现

  • 1844 例患者中 136 例(7.4%)在 52 周随访期间出现新发肾脏 flare。
  • 亚洲来源与新发肾脏 flare 风险升高相关(调整后风险比 [HRadj]:1.97;95% 置信区间 [CI]:1.32-2.94;P = 0.001)。
  • 基线抗双链 DNA(anti-dsDNA)阳性与新发肾脏 flare 风险升高相关(HRadj:1.32;95% CI:1.07-1.63;P = 0.008)。
  • 随访期间平均泼尼松剂量增加与新发肾脏 flare 风险升高相关(HRadj:1.03;95% CI:1.02-1.04;P < 0.001)。
  • 低剂量静脉贝利尤单抗(1 mg/kg 每月)使新发肾脏 flare 风险降低(HRadj:0.38;95% CI:0.20-0.73;P = 0.004)。

临床怎么用

  • 对于无肾炎的 SLE 患者,低剂量静脉贝利尤单抗(1 mg/kg 每月)或皮下贝利尤单抗(200 mg 每周)可能与降低新发肾脏 flare 风险相关。
  • 亚洲来源、基线 anti-dsDNA 阳性及随访中泼尼松剂量增加可能提示新发肾脏 flare 风险较高。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Belimumab was recently approved for treating lupus nephritis (LN), yet de novo LN cases during belimumab treatment given for nonrenal causes have been reported. Identification of reliable signals of impending flare is imperative. METHODS: We evaluated belimumab efficacy in preventing de novo renal flares and factors associated with renal flare occurrence in nephritis-naïve patients with systemic lupus erythematosus (SLE) who are receiving add-on belimumab or placebo in 5 phase 3 clinical trials using Cox regression analysis. RESULTS: Of 1844 eligible patients, 136 (7.4%) developed a de novo renal flare during a 52-week long follow-up. Asian origin (Adjusted Hazard Ratio [HRadj]: 1.97; 95% confidence interval [CI]: 1.32-2.94; P = 0.001), positive baseline anti-double stranded DNA (anti-dsDNA) levels (HRadj: 1.32; 95% CI: 1.07-1.63; P = 0.008), and increasing mean prednisone dose during follow-up (HRadj: 1.03; 95% CI: 1.02-1.04; P < 0.001) were associated with de novo renal flares. Low-dose intravenous (IV) belimumab (1 mg/kg monthly) yielded a nearly 3-fold lower hazard of de novo renal flare (HRadj: 0.38; 95% CI: 0.20-0.73; P = 0.004). Subcutaneous (SC) belimumab (200 mg weekly) also yielded a lower hazard (HRadj.: 0.69; 95% CI: 0.54-0.88; P = 0.003). The labeled IV dose (10 mg/kg monthly) conferred no clear protection (HRadj.: 0.74; 95% CI: 0.50-1.09; P = 0.127). CONCLUSION: We corroborated the substantial vulnerability of the Asian SLE population to renal affliction. Add-on low-dose IV belimumab (1 mg/kg) and SC belimumab appeared protective against renal flares in nephritis-naïve patients with SLE. The approved IV dose (10 mg/kg) yielded no clear protection.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Parodis I, Lindblom J, Cetrez N, et al. Effect of Belimumab on Preventing de novo Renal Lupus Flares. Kidney Int Rep. 2023. PMID: 37705915. doi:10.1016/j.ekir.2023.06.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。